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Radical View on the
ontractile Machinery
n Human Heart Failure*
erd Heusch, MD, Rainer Schulz, MD
ssen, Germany
he pathophysiology of heart failure (HF) has undergone
everal paradigm shifts over the last decades: from a clinical
iew with focus on dyspnea and congestion to a hemody-
amic view with focus on impaired ventricular geometry and
unction, and more recently, to a molecular view with focus
n impaired excitation-contraction coupling (1). None of
he more recent paradigms has rendered the prior ones
bsolete. HF is still a systemic circulatory condition char-
cterized by neurohumoral and inflammatory responses, as
ell as the involvement of multiple organs other than the
eart, and it is still an impairment of ventricular function as
eflected by pathologic alterations of the pressure-volume
iagram. The molecular view has focused on impaired
ardiomyocyte excitation-contraction coupling, which ulti-
ately results in a reduced calcium transient. More recently
lterations in the contractile machinery that responds to the
alcium transient have also been identified. A number of
enetic mutations in contractile proteins result in HF. With
espect to post-translational modification of contractile
roteins, the focus has been on their phosphorylation status.
nly recently, attention has been directed toward their
xidative modification.
See page 300
Clearly, oxidative stress is increased in HF. The forma-
ion of reactive oxygen species (ROS), mostly superoxide
nd hydroxyl radicals, and reactive nitrogen species (RNS) is
ncreased (2). Sources and targets of these reactive species
re multifold (Fig. 1); ROS originate from 1) mitochondria
i.e., from their respiratory chain, notably complex I and its
nteraction with p66shc; from complex III; and from mono-
minooxidase) (3); 2) NADPH oxidases, which are sarco-
emma associated and respond to activation of specific
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.t
From the Institut für Pathophysiologie, Universitätsklinikum Essen, Essen,
ermany. The authors have reported that they have no relationships to disclose.embrane receptors by their ligands, notably angiotensin II,
ndothelin, and cytokines (4); 3) xanthine oxidase (5); and
) uncoupled nitric oxide synthases in cardiomyocytes (6,7)
nd endothelial cells (8). The RNS originate from inducible
itric oxide synthase when its expression is increased (9) and
rom leukocytes, notably their myeloperoxidase (10). The
ormation of ROS, and possibly also that of RNS, is
overned by multiple positive feedback cycles. Subcellularly,
OS facilitate opening of the mitochondrial permeability
ransition pore, which upon opening induces inner mem-
rane depolarization, respiratory uncoupling, and further
OS formation (3,11). Extracellularly, systemic increases in
atecholamines, angiotensin, and cytokines activate specific
eceptors, promoting ROS formation from NADPH oxi-
ases and other intracellular sources.
Apart from oxidative modification of DNA and lipids,
OS and RNS modify proteins chemically by oxidation and
itros(yl)ation, respectively, and consequently alter their
unction and/or structural conformation (12). The exact
hemical modification of specific amino acids within
ardiac tissue under specific conditions is not clear in
etail, mostly because of methodologic reasons: among
any other forms of oxidative/nitrative protein modifi-
ations, there is primarily oxidation and nitros(yl)ation of
hiol residues in cysteine and methionine, oxidation and
itros(yl)ation of hydroxyl residues in tyrosine and thre-
nine, and carbonylation of proline, lysine, threonine,
nd arginine. The major subcellular targets of such
xidative protein modification are ion channels in sarco-
emma, sarcoplasmic reticulum, and mitochondria, which
romote further alterations in excitation-contraction
oupling and mitochondrial respiration. Increased free
adical formation in HF is not associated with increased
ntioxidant defenses; manganese superoxide dismutase
rotein expression and activity are largely decreased in
uman HF (13), further augmenting oxidative stress.
Di Lisa et al. (14,18) previously demonstrated that
rotein oxidation occurs with ischemia/reperfusion in iso-
ated rat and in situ pig hearts, and they related protein
xidation to contractile dysfunction. The dimerization of
ropomyosin, which has only a single cysteine residue and is
ross-linked after oxidation and disulfide formation, was
aken as evidence of protein oxidation, along with actin
arbonylation.
Canton et al. (14) extend these findings and—this is of
aramount merit—translate the concept of oxidative protein
odification to the human failing heart. By comparison
ith nonfailing donor hearts, which were excluded from
ransplantation, failing explanted hearts had increased car-
onylation of actin and tropomyosin and increased dimer-
zation and nitrosylation of tropomyosin (i.e., evidence for
xidative and nitrative protein modifications). Actin and
ropomyosin carbonylation as well as tropomyosin dimer-
zation were inversely related to left ventricular (LV) ejec-
ion fraction and positively to plasma troponin I (i.e., related
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January 18, 2011:310–2 A Radical Viewo functional and structural impairment with prognostic
elevance) (15,16). Apart from providing novel information,
he present report raises important questions, notably on the
pecificity of the observed oxidative protein modifications
nd on a potential cause-effect relationship between oxida-
ive protein modification and functional and/or structural
V impairment. It is unclear whether a specific HF patho-
hysiology creates a specific signature of oxidative protein
odification, possibly arising from specific reactive species
riginating from specific biochemical sources and targeting
pecific proteins, or whether oxidative protein modification
s an unspecific response in HF and its detection is largely
ependent on methodologic issues. The question of speci-
city extends from the underlying pathophysiology of HF
ischemia, dilated cardiomyopathy, myocarditis, and so on)
nto its localized (infarction) versus diffuse (microemboliza-
ion, dilated cardiomyopathy, myocarditis) expression, its
rreversible (infarction, scar) versus reversible (stunning,
ibernation) nature (17), and its temporal evolution. Al-
hough associative, this question relates also to the ejection
raction and plasma troponin data in the present report:
lasma troponin I reflects only recent and ongoing structural
amage, and sequential measures of ejection fraction are
eeded to judge potential reversibility.
With respect to causality, correlations of oxidative protein
odification to LV ejection fraction and plasma troponin can
nly be suggestive. The issue of causality obviously extends into
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Figure 1 Origins and Targets of Reactive Oxygen Species in th
CytC  cytochrome C; EC  endothelial cell; eNOS  endothelial nitric oxide synt
myeloperoxidase; MPTP  mitochondrial permeability transition pores; NF  nucle
XO  xanthine oxidase.otential therapeutic approaches. Reduction of tropomyosinimerization along with improved contractile function
as indeed achieved by vitamin C in pigs with coronary
icroembolization (18), and combined vitamins C and E
mproved LV function along with reduced tropomyosin
imerization in rabbits with pacing-induced HF (19).
In conclusion, a radical view on the contractile machinery
n failing human myocardium is worthwhile and promises
n avenue for therapeutic intervention, provided there is
adical progress in our mechanistic understanding.
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